Balancing Health and the Holidays
By Codi Darnell December 14, 2021 ‘Tis the season for twinkle lights, traditions and totally neglecting the management of our chronic conditions. Yes, the holiday season is upon us. Calendars fill up quickly with school concerts, work parties, family dinners and friend get-togethers. Not to mention the shopping, wrapping, cookie decorating and Hallmark movie watching. […]
NervGen Pharma Corp. Closes Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, Canada. November 29, 2021— NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” the “Company”), a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, is pleased to announce that it has closed a […]
NervGen Pharma Reports Third Quarter 2021 Results
Vancouver, Canada. November 18, 2021 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, today reported its financial and operational results for the third quarter ended September 30, 2021. “Most notably, we made important progress […]
The Perks and Pitfalls of Accessible Parking
By Codi Darnell November 16, 2021 “I’m only in it for the parking.” Whether it’s written on a t-shirt or a bumper sticker, it’s an easy joke for many of us in the disabled community to make. When you enter a packed parking lot and see an empty spot with that bright blue square […]
NervGen Pharma Completes $9.2 Million Bought Deal Financing
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, Canada November 12, 2021 – NervGen Pharma Corp., (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, is pleased to announce the closing of its previously announced public […]
NervGen Pharma Announces Increase to Bought Deal Financing to $8.0 Million
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, Canada November 5, 2021 – NervGen Pharma Corp., (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, is pleased to announce that, due to strong demand, the Company […]
NervGen Pharma Announces $5,000,000 Bought Deal Financing
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Vancouver, Canada November 4, 2021 – NervGen Pharma Corp., (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, is pleased to announce that it has entered into an agreement […]
NervGen Presents Additional Phase 1 Clinical Trial Data for NVG-291 at Neuroscience 2021 / Safety Review Committee Provides Recommendation to Proceed to Multiple Ascending Dose Portion of the Trial
Vancouver, Canada. November 4, 2021 – NervGen Pharma Corp., (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, provided an update on its Phase 1 program with NVG-291 at the Society for Neuroscience’s Neuroscience 2021 conference. NervGen’s Chief Medical Officer, Dr. Daniel […]
The Cost of Disability
By Codi Darnell November 2, 2021 The monthly budget – while I love a good spreadsheet (seriously, I’m a bit of a nerd), this one is not it. If my computer was an attic, my Monthly Budget spreadsheet would be loose in the back of a binder, the three holes ripped open long ago, and […]
NervGen Pharma Announces Spinal Cord Injury Clinical Advisory Board
Vancouver, Canada. October 27, 2021 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQX: NGENF) (“NervGen” or the “Company”), a clinical stage biotech company dedicated to creating innovative treatments for nervous system damage, today announced the formation of its Spinal Cord Injury (SCI) Clinical Advisory Board comprised of five world-class scientific and clinical researchers in the field […]